Table: Taisho Pharmaceutical HD -Q1 group results
Aug 1 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2016 Jun 30, 2015 Mar 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 69.43 69.21 285.00
(+0.3 pct) (+1.2 pct) (-1.8 pct)
Operating 9.11 5.23 29.50
(+74.0 pct) (-39.2 pct) (+2.2 pct)
Recurring 10.42 7.49 36.50
(+39.1 pct) (-30.4 pct) (-0.7 pct)
Net 6.95 4.69 24.00
(+48.2 pct) (-29.6 pct) (+6.8 pct)
EPS 86.92 yen 57.81 yen 300.37 yen
EPS Diluted 86.86 yen 57.78 yen
Ann Div 100.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10